+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Fibromyalgia Therapeutics Market - Global Forecast 2026-2032- Product Image
Fibromyalgia Therapeutics Market - Global Forecast 2026-2032- Product Image
New

Fibromyalgia Therapeutics Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 194 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 5887861
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The fibromyalgia therapeutics market is being redefined by evolving clinical practices, regulatory expectations, and patient-centric care, challenging industry leaders to align innovation, operational agility, and strong market access strategies for long-term success.

Market Snapshot: Fibromyalgia Therapeutics Market

The Fibromyalgia Therapeutics Market is projected to grow from USD 3.85 billion in 2025 to USD 4.04 billion in 2026, with continued growth anticipated at a CAGR of 5.66%. By 2032, the market is expected to reach USD 5.66 billion. This expansion is driven by multidimensional clinical and commercial shifts, heightened scientific research, and changing regulatory frameworks influencing therapeutic development and market penetration.

Scope & Segmentation

  • Drug Classes: Anticonvulsants, selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, tricyclic antidepressants, with further differentiation into branded and generic formulations for each class.
  • Routes of Administration: Oral, parenteral, and topical, each presenting distinctive trial designs, adherence factors, and manufacturing needs.
  • Distribution Channels: Hospital pharmacies, online pharmacies, and retail pharmacies, all requiring tailored approaches for compliance and patient engagement.
  • End-User Settings: Home care, hospital-based therapy, and specialty clinics, each shaping patient education models and inventory management.
  • Regional Coverage: Americas, Europe Middle East & Africa, and Asia-Pacific markets, reflecting regulatory complexity, payer behaviors, and diverse clinical practice standards.
  • Technology & Delivery Innovations: Digital health platforms, remote monitoring, and hybrid care delivery models support evidence generation and improve patient adherence.

Key Takeaways

  • Breakthroughs in neurobiology and translational research have expanded therapeutic targets beyond traditional symptomatic pain management, enabling more stratified treatment strategies.
  • Regulatory bodies increasingly require incorporation of patient-reported outcomes and functional endpoints, prompting a shift in trial design and evidence expectations for market authorization and reimbursement.
  • Patient advocacy and clinician collaboratives are raising the bar for quality-of-life metrics and cognitive function, now influencing clinical development and payer negotiations.
  • Specialty biotechs are emerging as key innovators, while established pharmaceutical firms continue to leverage broad market reach and lifecycle management expertise. Generic manufacturers remain vital for access and affordability.
  • Digital health and telemedicine support hybrid care models and real-world evidence collection, strengthening longitudinal patient monitoring and adherence.
  • Scenario-based planning and cross-functional alliances are gaining relevance as market access becomes more competitive and supply chain risks increase.

Tariff Impact Across the Therapeutics Value Chain

  • Recent U.S. tariff adjustments affect supply chain economics, prompting shifts toward local or regional sourcing and increasing the focus on manufacturing resilience.
  • Manufacturers are mitigating cost volatility via dual sourcing, lead time adjustments, and alternative supplier qualification, impacting inventory strategies and production continuity.
  • Procurement leaders and supply chain executives are emphasizing scenario planning and collaborative supplier relationships to safeguard from compliance delays and disruptions at ports of entry.
  • End-to-end supply chain strategies now more directly influence therapeutic accessibility and cost management for patients in this sector.

Methodology & Data Sources

Research methodologies integrated structured interviews with clinicians, clinical trial investigators, payers, and supply chain professionals. Systematic literature synthesis included peer-reviewed journals, regulatory guidance, and policy documents. Scenario mapping and thematic analysis were utilized to validate findings. Triangulation processes ensured robustness and relevance of clinical and commercial insights.

Why This Report Matters

  • Enables senior leaders to benchmark clinical, regulatory, and commercial priorities as fibromyalgia care becomes more evidence-driven and segmented.
  • Supports strategic planning across therapeutic development, manufacturing, and market access by illuminating region-specific challenges and innovation opportunities.
  • Provides risk-mitigating recommendations for tariff-related supply chain restructuring and market resilience.

Conclusion

This report enables industry decision-makers to design integrated strategies, adapt to evolving stakeholder demands, and seize emerging opportunities in the changing fibromyalgia therapeutics market.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Fibromyalgia Therapeutics Market, by Drug Class
8.1. Anticonvulsants
8.1.1. Branded
8.1.2. Generic
8.2. Selective Serotonin Reuptake Inhibitors
8.2.1. Branded
8.2.2. Generic
8.3. Serotonin And Norepinephrine Reuptake Inhibitors
8.3.1. Branded
8.3.2. Generic
8.4. Tricyclic Antidepressants
8.4.1. Branded
8.4.2. Generic
9. Fibromyalgia Therapeutics Market, by Route Of Administration
9.1. Oral
9.2. Parenteral
9.3. Topical
10. Fibromyalgia Therapeutics Market, by Distribution Channel
10.1. Hospital Pharmacy
10.2. Online Pharmacy
10.3. Retail Pharmacy
11. Fibromyalgia Therapeutics Market, by End User
11.1. Home Care
11.2. Hospital
11.3. Specialty Clinics
12. Fibromyalgia Therapeutics Market, by Region
12.1. Americas
12.1.1. North America
12.1.2. Latin America
12.2. Europe, Middle East & Africa
12.2.1. Europe
12.2.2. Middle East
12.2.3. Africa
12.3. Asia-Pacific
13. Fibromyalgia Therapeutics Market, by Group
13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO
14. Fibromyalgia Therapeutics Market, by Country
14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea
15. United States Fibromyalgia Therapeutics Market
16. China Fibromyalgia Therapeutics Market
17. Competitive Landscape
17.1. Market Concentration Analysis, 2025
17.1.1. Concentration Ratio (CR)
17.1.2. Herfindahl Hirschman Index (HHI)
17.2. Recent Developments & Impact Analysis, 2025
17.3. Product Portfolio Analysis, 2025
17.4. Benchmarking Analysis, 2025
17.5. AbbVie Inc.
17.6. Amgen Inc.
17.7. Amicus Therapeutics
17.8. Astellas Pharma Inc
17.9. AstraZeneca plc
17.10. Bayer AG
17.11. Biogen Inc.
17.12. BioMarin Pharmaceutical Inc
17.13. C.H. Boehringer Sohn AG & Co. KG
17.14. Eli Lilly and Company
17.15. Gilead Sciences, Inc.
17.16. GlaxoSmithKline (GSK)
17.17. Jazz Pharmaceuticals plc
17.18. Johnson & Johnson Services, Inc.
17.19. Kyowa Kirin Co, Ltd
17.20. Merck & Co., Inc.
17.21. Novartis AG
17.22. Pfizer inc.
17.23. Regeneron Pharmaceuticals, Inc.
17.24. Roche Holding AG
17.25. Sanofi S.A.
17.26. Sarepta Therapeutics, Inc.
17.27. Takeda Pharmaceutical Company
17.28. Teva Pharmaceutical Industries Ltd.
17.29. The Bristol-Myers Squibb Company
17.30. Vertex Pharmaceuticals Incorporated
17.31. Viatris inc.
List of Figures
FIGURE 1. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. UNITED STATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 12. CHINA FIBROMYALGIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY BRANDED, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY BRANDED, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY GENERIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY GENERIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY BRANDED, BY REGION, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY BRANDED, BY GROUP, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY GENERIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY GENERIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY BRANDED, BY REGION, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY BRANDED, BY GROUP, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY GENERIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY GENERIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY BRANDED, BY REGION, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY BRANDED, BY GROUP, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY GENERIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY GENERIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 74. AMERICAS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 75. AMERICAS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 76. AMERICAS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
TABLE 77. AMERICAS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 78. AMERICAS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 79. AMERICAS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
TABLE 80. AMERICAS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 81. AMERICAS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 82. AMERICAS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 83. NORTH AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 84. NORTH AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 85. NORTH AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
TABLE 86. NORTH AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 87. NORTH AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 88. NORTH AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
TABLE 89. NORTH AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 90. NORTH AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 91. NORTH AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 92. LATIN AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 93. LATIN AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 94. LATIN AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
TABLE 95. LATIN AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 96. LATIN AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 97. LATIN AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
TABLE 98. LATIN AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 99. LATIN AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 100. LATIN AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 108. EUROPE, MIDDLE EAST & AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 110. EUROPE FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 111. EUROPE FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 112. EUROPE FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
TABLE 113. EUROPE FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 114. EUROPE FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 115. EUROPE FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
TABLE 116. EUROPE FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 117. EUROPE FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 118. EUROPE FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 119. MIDDLE EAST FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 120. MIDDLE EAST FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 121. MIDDLE EAST FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
TABLE 122. MIDDLE EAST FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 123. MIDDLE EAST FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 124. MIDDLE EAST FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
TABLE 125. MIDDLE EAST FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 126. MIDDLE EAST FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 127. MIDDLE EAST FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 128. AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 129. AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 130. AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
TABLE 131. AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 132. AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 133. AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
TABLE 134. AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 135. AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 136. AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 137. ASIA-PACIFIC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 138. ASIA-PACIFIC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 139. ASIA-PACIFIC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
TABLE 140. ASIA-PACIFIC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 141. ASIA-PACIFIC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 142. ASIA-PACIFIC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
TABLE 143. ASIA-PACIFIC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 144. ASIA-PACIFIC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 145. ASIA-PACIFIC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 146. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 147. ASEAN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 148. ASEAN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 149. ASEAN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
TABLE 150. ASEAN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 151. ASEAN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 152. ASEAN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
TABLE 153. ASEAN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 154. ASEAN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 155. ASEAN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 156. GCC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 157. GCC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 158. GCC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
TABLE 159. GCC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 160. GCC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 161. GCC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
TABLE 162. GCC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 163. GCC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 164. GCC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 165. EUROPEAN UNION FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 166. EUROPEAN UNION FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 167. EUROPEAN UNION FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
TABLE 168. EUROPEAN UNION FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 169. EUROPEAN UNION FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 170. EUROPEAN UNION FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
TABLE 171. EUROPEAN UNION FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 172. EUROPEAN UNION FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 173. EUROPEAN UNION FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 174. BRICS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 175. BRICS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 176. BRICS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
TABLE 177. BRICS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 178. BRICS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 179. BRICS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
TABLE 180. BRICS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 181. BRICS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 182. BRICS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 183. G7 FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 184. G7 FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 185. G7 FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
TABLE 186. G7 FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 187. G7 FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 188. G7 FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
TABLE 189. G7 FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 190. G7 FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 191. G7 FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 192. NATO FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 193. NATO FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 194. NATO FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
TABLE 195. NATO FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 196. NATO FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 197. NATO FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
TABLE 198. NATO FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 199. NATO FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 200. NATO FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 201. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 202. UNITED STATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 203. UNITED STATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 204. UNITED STATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
TABLE 205. UNITED STATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 206. UNITED STATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 207. UNITED STATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
TABLE 208. UNITED STATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 209. UNITED STATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 210. UNITED STATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 211. CHINA FIBROMYALGIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 212. CHINA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 213. CHINA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
TABLE 214. CHINA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 215. CHINA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 216. CHINA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
TABLE 217. CHINA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 218. CHINA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 219. CHINA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Fibromyalgia Therapeutics market report include:
  • AbbVie Inc.
  • Amgen Inc.
  • Amicus Therapeutics
  • Astellas Pharma Inc
  • AstraZeneca plc
  • Bayer AG
  • Biogen Inc.
  • BioMarin Pharmaceutical Inc
  • C.H. Boehringer Sohn AG & Co. KG
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline (GSK)
  • Jazz Pharmaceuticals plc
  • Johnson & Johnson Services, Inc.
  • Kyowa Kirin Co, Ltd
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sanofi S.A.
  • Sarepta Therapeutics, Inc.
  • Takeda Pharmaceutical Company
  • Teva Pharmaceutical Industries Ltd.
  • The Bristol-Myers Squibb Company
  • Vertex Pharmaceuticals Incorporated
  • Viatris inc.

Table Information

Report AttributeDetails
No. of Pages194
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 4.04 Billion
Forecasted Market Value ( USD ) by 2032 $ 5.66 Billion
Compound Annual Growth Rate5.6%
Regions CoveredGlobal
No. of Companies Mentioned28

Related Topics

Related Reports

Fibromyalgia Treatment Market - Global Strategic Business Report - Product Image

Fibromyalgia Treatment Market - Global Strategic Business Report

  • Report
  • 276 Pages
  • Global
From
Fibromyalgia Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa) - Product Image

Fibromyalgia Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • Report
  • 250 Pages
  • Global
From
Fibromyalgia Therapeutics - Global Strategic Business Report - Product Image

Fibromyalgia Therapeutics - Global Strategic Business Report

  • Report
  • 263 Pages
  • Global
From
Fibromyalgia Market - A Global and Regional Analysis: Focus on Treatment Type and Region - Analysis and Forecast, 2025-2035 - Product Image

Fibromyalgia Market - A Global and Regional Analysis: Focus on Treatment Type and Region - Analysis and Forecast, 2025-2035

  • Report
  • Global
From
Fibromyalgia Treatment Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034 - Product Image

Fibromyalgia Treatment Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034

  • Report
  • 135 Pages
  • Global
From

About the Fibromyalgia Drug Market

The Fibromyalgia Drug market is a subset of the Immune Disorders Drugs market, which includes treatments for a variety of conditions related to the immune system. Fibromyalgia is a chronic disorder characterized by widespread musculoskeletal pain, fatigue, and tenderness in localized areas. Fibromyalgia drugs are used to reduce pain, improve sleep, and reduce fatigue. Commonly prescribed drugs include antidepressants, anticonvulsants, and muscle relaxants. Other treatments include physical therapy, cognitive behavioral therapy, and lifestyle modifications. The Fibromyalgia Drug market is highly competitive, with a number of companies offering treatments. Some of the major players in the market include Pfizer, Eli Lilly, Merck, and Novartis. Other companies include AbbVie, Allergan, and Teva Pharmaceuticals. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.